| Literature DB >> 36160124 |
Wen Xu1, Juan Du2,3, Ting-Ting Wei2,3, Lin-Yi Chen2,3, Xin-Xin Yang1, Tu Bo1, Han-Yu Liu2,3, Ming-Zhu Xie2,3, Tian-Shuo Zhao2,3, Jun-Lian Yang1, Fuqiang Cui2,3, Wei-Wei Chen1, Qing-Bin Lu2,3.
Abstract
Objectives: The changes in metabolism by human adenovirus (HAdV) infection was unclear. The potential mechanism of HAdV-7 causing acute respiratory tract infection was explored.Entities:
Keywords: acute respiratory tract infection; bile acids; cytokines; human adenovirus; metabolomics
Year: 2022 PMID: 36160124 PMCID: PMC9489940 DOI: 10.3389/fmed.2022.896409
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
FIGURE 1Analysis of untargeted metabolomics between cases and healthy controls. (A) Shows the classification of all metabolites that were screened. “*”p < 0.05; the number of % represent for the ratio of the number of differential metabolites with P < 0.05 to each class. (B) Shows the clustering results of the metabolites at the top 60 of VIP among PA, AA, and HC. (C) Shows the PCA of samples from the three groups. (D) Shows the 3D OPLS-DA scatter plot for HC and AA. (E) Shows the 3D OPLS-DA scatter plot between AA and AF. (F) Shows the 3D OPLS-DA scatter plot between the PA and PR. (G) Shows the 3D OPLS-DA scatter plot between PA and PF. PA, patients in the acute stage; AA, asymptomatic cases at the acute stage; HC, healthy controls; AF, asymptomatic cases at the follow-up stage; PR, patients at the recovery stage; PF, patients in the follow-up stage.
FIGURE 2Differential metabolites and metabolic pathway enrichment via untargeted metabolomics analysis. (A) Shows the classes of differentially accumulated metabolites between PA and AA and HC. (B,C) Show the concentrations of the taurocholic acid and glycocholic acid among PA, AA, and HC, respectively. (D,E) Show the enrichment of PA and AA metabolic pathways, respectively. PA, patients in the acute stage; AA, asymptomatic cases in the acute stage; HC, healthy controls.
FIGURE 3Analysis of targeted metabolomics between cases and healthy controls. (A) Shows the clustering results of the bile acid P among PA, AA, and HC. (B,C) Show the 3D OPLS-DA scatter plot for PA, AA, and HC, respectively. (D–F) Show the concentrations of thirteen bile acids in PA, AA, and HC. PA: patients in the acute stage. AA, asymptomatic cases at the acute stage; HC, healthy controls.
FIGURE 4The levels of cytokines and peripheral lymphocyte subsets at the different levels of bile acids were significantly different between the patients and asymptomatic cases. (A–G) Show the levels of seven cytokines between the high and low of bile acid levels with significant differences. (H–K) Show the contents of four peripheral lymphocyte subsets between high and low bile acid levels with significant difference *p < 0.05.
FIGURE 5Effects of bile acids, including TCA and GCDCA, on HAdV-7 replication in the A549 cell line. (A–H) Show the cytopathic effect via microscopy observations; (A) the blank control for TCA test; (B) the blank control with TCA; (C) the HAdV-7-treated cells; (D) the HAdV-7-treated cell with TCA; (E) the blank control for GCDCA test; (F) the blank control with GCDCA; (G) the HAdV-7-treated cells; (H) the HAdV-7-treated cell with GCDCA). (I–N) Show the viral load in the blank control and HAdV-7 infection groups with or without bile acids at a MOI = 1. (I) Total viral loads with TCA; (J) viral loads with TCA in cell lysates; (K) viral loads with TCA in supernatants; (L) total viral loads with GCDCA; (M) viral loads with GCDCA in cell lysates; (N) viral loads with GCDCA in supernatants. All the experiments were repeated for six times *p < 0.05.